Treatment with the highly selective IDH1 inhibitor ivosidenib led to a complete remission rate of 40%, with an overall survival of nearly 19 months in this group. Daniel Pollyea, MD, MS, shares results from this phase 1 study.
Recent Articles
Trump Administration Considering Democratic Senator’s Drug Pricing Proposal
In early July, Senate Finance Committee Chairman Chuck Grassley (R-IA) met with Republican committee members to discuss a potential agreement that he and Sen....
Former VP Biden Wants to Usher in The Next Generation of the Affordable Care...
Democratic presidential candidate and former Vice President Joe Biden released his health care plan, which primarily builds on the Affordable Care Act (ACA) while...
Study Finds Millions of Caregivers Perform Complex Medical Tasks
Almost 20 million U.S. residents are performing complex medical and nursing tasks for those they care for, performing duties generally reserved for health-care professionals,...
Suboxone Manufacturer Fined $1.4 Billion Over Illegal Marketing
Reckitt Benckiser, now known as Indivior, will pay the U.S. government a record settlement fee of $1.4 billion to resolve multiple investigations related to...
Capping Trainees’ Work Hours Does Not Harm Patient Care
Limiting the number of hours that doctors in training work to 80 hours per week had no adverse effects on patient care, according to...
Current Issue
July 2019 Bonus Mid-Year Edition, Volume 5, Issue 9
This issue features a look at research espionage, coverage from the ASCO and EHA annual meetings, and more.
